News
13h
Stocktwits on MSNEli Lilly’s Newest Obesity Drug Candidate Stirs Wall Street Buzz, But Not Everyone’s SoldEli Lilly's experimental obesity therapy bimagrumab drew mixed reactions from Wall Street after the company recently ...
Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...
While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...
Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, ...
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results